Congressional Decision To Disband OTA Prompts Dire Warnings From Supporters

STRONG WORDS: OSTP's Skip Johns blasts Congress for its "shortsighted act". Only a presidential veto--or a last-minute change of heart--could have stopped the Republican-led Congress from abolishing its only in-house source of science-policy analysis, the 23-year-old Office of Technology Assessment. But a threatened veto is now unlikely to come, and Congress has voted and moved on to other matters. OTA is history. On July 27, House and Senate conferees sealed the agency's fate in H.R. 104-21

Written bySteve Sternberg
| 5 min read

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share

OTA is history.

On July 27, House and Senate conferees sealed the agency's fate in H.R. 104-212, the Legislative Branch Appropriations bill for fiscal 1996. It is a compromise measure that sets funding limits for Congress and its agencies, including the Library of Congress and the Congressional Budget Office. It is also the first such bill in nearly a quarter of a century to omit funding for OTA.

OTA director Roger Herdman calls the vote "unfortunate" for the agency, Congress, and the United States.

"In 1972," he observes, "when OTA was established, Congress understood that if it relied on the executive branch or the private sector it would get advice that would reflect the agendas of the executive branch or private agencies. I still don't think they're going to be able to get what OTA gave them in any other way than from OTA."

Herdman says that the committee provided ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies